Elite Pharmaceuticals, Inc.
ELTP
$0.26
$0.00-1.08%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 33.72% | 77.13% | 100.18% | 72.67% | 58.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.72% | 77.13% | 100.18% | 72.67% | 58.70% |
| Cost of Revenue | 71.00% | 67.99% | 75.43% | 47.89% | 28.18% |
| Gross Profit | 4.19% | 87.16% | 131.47% | 103.30% | 95.60% |
| SG&A Expenses | 67.80% | 92.57% | 28.61% | 47.83% | 39.41% |
| Depreciation & Amortization | -8.25% | -8.32% | -4.31% | 3.94% | 12.20% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.44% | 57.40% | 52.95% | 39.89% | 24.37% |
| Operating Income | -8.32% | 135.62% | 324.49% | 199.57% | 199.13% |
| Income Before Tax | 4,546.08% | 109,148.75% | 418.69% | 450.63% | -10,483.69% |
| Income Tax Expenses | -9.88% | 180.15% | 1,702.49% | 2,658.43% | 147.79% |
| Earnings from Continuing Operations | 623.97% | 1,140.02% | 341.34% | 317.96% | -155.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 623.97% | 1,140.02% | 341.34% | 317.96% | -155.23% |
| EBIT | -8.32% | 135.62% | 324.49% | 199.57% | 199.13% |
| EBITDA | -8.32% | 125.00% | 285.41% | 180.81% | 180.38% |
| EPS Basic | 621.78% | 1,142.50% | 343.98% | 328.07% | -152.33% |
| Normalized Basic EPS | 38,200.00% | 3,622.22% | 427.72% | 396.00% | 109.09% |
| EPS Diluted | 280.82% | 380.00% | 186.87% | 112.36% | -228.07% |
| Normalized Diluted EPS | 35,600.00% | 3,355.56% | 415.84% | 386.00% | 109.09% |
| Average Basic Shares Outstanding | 0.63% | 0.42% | 1.39% | 2.56% | 3.82% |
| Average Diluted Shares Outstanding | 7.64% | 6.04% | 4.05% | 3.41% | 2.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |